+91-8668442535

Non-Hormonal Alternatives for Menopause Market by Indication (Hot Flashes, Vaginal Dryness, Others (Chills, Night Sweats, Sleep Problems, Mood Changes, etc.)) by Therapy (Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Plant-derived estrogens (phytoestrogens), Herbal treatments, Over-the-counter therapies, Others) by Application – Ukraine War, Future Prospects And Competitive Analysis, 2016 - 2028

With the ever-increasing population of women reaching menopause worldwide, the demand for Non-Hormonal Alternatives for Menopause is proliferating and has bagged the revenue of USD 7,929 million in 2021. Moreover, the need for Non-Hormonal Alternatives for Menopause is likely to exhibit a rapid CAGR of over 7.5% over the forecast period to reach the valuation of USD 13,465 million in 2028. Meanwhile, the cumulative revenue growth opportunity offered by the global Non-Hormonal Alternatives for Menopause market is expected to reach over USD 76.5 billion between 2022 and 2028.

Non-Hormonal Alternatives for Menopause Market

Interesting Facts about Non-Hormonal Alternatives for Menopause Industry

  • More than 2 million women reach menopause in the U.S. alone, and over 40 million worldwide
  • Over 60 to 70 percent of women reaching menopause face problems such as hot flashes
  • Antidepressants are most widely used to treat hot flashes
  • S. accounted for over 30% share of the revenue generated by the Non-Hormonal Alternatives for Menopause market
  • Europe is the second leading market for Non-Hormonal Alternatives for Menopause

Risk Associated with Hormonal Replacement Therapy to Drive the Demand for Non-Hormonal Alternatives for Menopause

Despite its efficiency, hormonal replacement therapy is not considered the first choice of treatment for menopause in women. The reason is hormonal replacement therapy has been considered a potential risk for the development of breast cancer in women. In addition, since a study published by the Women's Health Initiative, physicians have become reluctant to prescribe hormone replacement therapy. Over two-thirds of women facing such problems are given Non-Hormonal Alternatives for Menopause symptoms.

Antidepressants to Trigger the Growth of Non-Hormonal Alternatives for Menopause    

Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Plant-derived estrogens (phytoestrogens), Herbal treatments, Over-the-counter therapies, and Others are effective therapies used for the treatment of menopause. Non-hormonal treatments for vasomotor symptoms include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), which reduce HF severity and frequency by 20 to 65 percent. Since HFs are considered to be caused by alterations in thermoregulation caused by estrogen shortage, which leads to a drop in serotonin levels, the blockade of serotonin and norepinephrine receptors induced by SSRIs and SNRIs may help to counteract this imbalance. Although several studies have examined the efficacy of SSRIs and SNRIs in lowering HFs, paroxetine salt 7.5 mg/day is the only FDA-approved medicine for treating moderate-to-severe vasomotor symptoms in postmenopausal women.

Hot Flashes to Drive the Demand for Non-Hormonal Alternatives for Menopause

Hot Flashes, Vaginal Dryness, and Others (Chills, Night Sweats, Sleep Problems, Mood Changes, etc.0 are some of the significant indications that drive the demand for Non-Hormonal Alternatives for Menopause. Hot flashes are the most common of all menopause symptoms, affecting over 85% of women undergoing menopause symptoms. In contrast, vaginal dryness accounts for the second largest share of revenue generated by the Non-Hormonal Alternatives for Menopause market. Therefore, it is also expected to exhibit rapid growth over the forecast period.

The Asia Pacific to Witness Rapid Growth in Demand for Non-Hormonal Alternatives for Menopause

Strong growth in demand for Non-Hormonal Alternatives for Menopause in China, India, South Korea, and Japan is leading the development of the Asia Pacific market. The massive population of women in China and India and the large number of women reaching menopause every year, coupled with increasing health awareness and growing per capita expenditure on healthcare in the region, is another factor fueling the growth of Non-Hormonal Alternatives for Menopause. While the U.S. is the leading market for Non-Hormonal Alternatives for Menopause, with over 25% share in the global Non-Hormonal Alternatives for Menopause market. A high level of awareness, higher spending power, higher penetration of alternative therapies, etc., is mainly responsible for the strong growth of Non-Hormonal Alternatives for Menopause in the U.S. Similarly, Europe also holds a significant position in the global Non-Hormonal Alternatives for Menopause market.  Germany, UK and France are leading overall growth of European Non-Hormonal Alternatives for Menopause market.

Strong Product Pipeline and Focus on Innovation to Propel the Future Growth of Non-Hormonal Alternatives for Menopause   

Swor Women's Care, Paladin Labs, Boehringer Ingelheim, Pfizer, Organon Inc., Lupin and GSK are some of the leading players in global Non-Hormonal Alternatives for Menopause market. There are large number of players operating in the global Non-Hormonal Alternatives for Menopause market. Key players have invested huge amount of sum on the development of new therapies for menopause. There is strong pipeline of Non-Hormonal Alternatives for Menopause. Banking on their strong R&D capabilities, companies are thriving to bring innovative alternatives to hormonal therapies with no compromise in their efficiency.

Frequently asked questions about global Non-Hormonal Alternatives for Menopause industry

COVID 19 had a little impact on growth of Non-Hormonal Alternatives for Menopause market and growth declined to 7.68% in 2020 as against 14.50% in 2019

U.S. is the largest regional market with highest share in the total revenue generation of Non-Hormonal Alternatives for Menopause consumed in 2021

Ever increasing health awareness and growing incidence rate of hot flashes among women reaching menopause age

Hot Flashes segment dominated the Non-Hormonal Alternatives for Menopause market in 2021 with over 40% share

Selective serotonin reuptake inhibitors (SSRIs) segment was the largest end-user of Non-Hormonal Alternatives for Menopause in 2021 with over 20% share

Non-Hormonal Alternatives for Menopause Market

Report Attribute Details
Market Value in 2021 USD 7,929.16 million
Market Value in 2028 USD 13,465.59 million
CAGR 7.57% between 2021 and 2028
Benchmarking Year 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2022
Category:  Medical Devices
Report ID:   60540
Report Format:   PDF
Pages:   189
Rating:    4.8 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support